A securities class action lawsuit has been filed against Rocket Pharmaceuticals, Inc., a gene therapy company based in Cranbury, New Jersey. The lawsuit is on behalf of investors who purchased the company's stock between September 17, 2024, and May 26, 2025, and suffered losses due to alleged material misstatements and omissions. The claims revolve around the company's failure to disclose significant safety-related updates in its RP-A501 clinical trial, which included the use of an immunomodulatory agent, prior to a fatal adverse event and an FDA-imposed clinical hold. Following the public confirmation of the trial hold and patient death on May 28, 2025, Rocket Pharmaceuticals' shares saw a significant drop from $6.27 to $2.33. Investors seeking to serve as lead plaintiff in the case have until August 11, 2025, to come forward.